1. Choung RS, Locke GR 3rd (2011) Epidemiology of IBS. Gastroenterol Clin N Am 40(1):1–10

2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130(5):1480–1491

3. Mayer EA (2011) Gut feelings: the emerging biology of gut–brain communication. Nat Rev Neurosci 12(8):453–466

4. Quigley EM (2006) Changing face of irritable bowel syndrome. World J Gastroenterol 12(1):1–5

5. Simren M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG, Rome Foundation C (2013) Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 62(1):159–176

6. El-Salhy M (2015) Recent developments in the pathophysiology of irritable bowel syndrome. World J Gastroenterol 21(25):7621–7636

7. Chey WD, Kurlander J, Eswaran S (2015) Irritable bowel syndrome: a clinical review. JAMA 313(9):949–958

8. De Palma G, Collins SM, Bercik P (2014) The microbiota–gut–brain axis in functional gastrointestinal disorders. Gut Microbes 5(3):419–429

9. Zhou XY, Li M, Li X, Long X, Zuo XL, Hou XH, Cong YZ, Li YQ (2016) Visceral hypersensitive rats share common dysbiosis features with irritable bowel syndrome patients. World J Gastroenterol 22(22):5211–5227

10. Catanzaro R, Occhipinti S, Calabrese F, Anzalone MG, Milazzo M, Italia A, Marotta F (2014) Irritable bowel syndrome: new findings in pathophysiological and therapeutic field. Minerva Gastroenterol Dietol 60(2):151–163

11. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489(7415):220–230

12. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T, Clarke JM, Topping DL, Suzuki T et al (2011) Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469(7331):543–547

13. Sonnenburg JL, Xu J, Leip DD, Chen CH, Westover BP, Weatherford J, Buhler JD, Gordon JI (2005) Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science 307(5717):1955–1959

14. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP et al (2012) Human gut microbiome viewed across age and geography. Nature 486(7402):222–227

15. Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, Glickman JN, Siebert R, Baron RM, Kasper DL et al (2012) Microbial exposure during early life has persistent effects on natural killer T cell function. Science 336(6080):489–493

16. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI (2008) Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3(4):213–223

17. Ley RE, Turnbaugh PJ, Klein S, Gordon JI (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444(7122):1022–1023

18. Yamaguchi Y, Adachi K, Sugiyama T, Shimozato A, Ebi M, Ogasawara N, Funaki Y, Goto C, Sasaki M, Kasugai K (2016) Association of intestinal microbiota with metabolic markers and dietary habits in patients with type 2 diabetes. Digestion 94(2):66–72

19. Lupton JR (2004) Microbial degradation products influence colon cancer risk: the butyrate controversy. J Nutr 134(2):479–482

20. Dicksved J, Halfvarson J, Rosenquist M, Jarnerot G, Tysk C, Apajalahti J, Engstrand L, Jansson JK (2008) Molecular analysis of the gut microbiota of identical twins with Crohn’s disease. ISME J 2(7):716–727

21. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104(34):13780–13785

22. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G (1982) The fecal microbial population in the irritable bowel syndrome. Microbiologica 5(3):185–194

23. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133(1):24–33

24. Jeffery IB, O’Toole PW, Ohman L, Claesson MJ, Deane J, Quigley EM, Simren M (2012) An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 61(7):997–1006

25. Malinen E, Rinttila T, Kajander K, Matto J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A (2005) Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 100(2):373–382

26. Mättö J, Maunuksela L, Kajander K et al (2005) Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome—a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 43:213–222

27. Lyra A (2009) Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol 15(47):5936

28. Parkes GC, Rayment NB, Hudspith BN, Petrovska L, Lomer MC, Brostoff J, Whelan K, Sanderson JD (2012) Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil 24(1):31–39

29. Kerckhoffs APM (2009) Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 15(23):2887

30. Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, Weidler EM, Qin X, Coarfa C, Milosavljevic A et al (2011) Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 141(5):1782–1791

31. Rajilić-Stojanović M, Biagi E, HGHJ H, Kajander K, Kekkonen RA, Tims S, de Vos WM (2011) Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141(5):1792–1801

32. Si JM, Yu YC, Fan YJ, Chen SJ (2004) Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 10(12):1802–1805

33. Carroll IM, Chang YH, Park J, Sartor RB, Ringel Y (2010) Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathogens 2(1):19

34. Krogius-Kurikka L, Lyra A, Malinen E, Aarnikunnas J, Tuimala J, Paulin L, Makivuokko H, Kajander K, Palva A (2009) Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 9:95

35. Sundin J, Rangel I, Fuentes S, Heikamp-de Jong I, Hultgren-Hornquist E, de Vos WM, Brummer RJ (2015) Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther 41(4):342–351

36. Jalanka-Tuovinen J, Salojarvi J, Salonen A, Immonen O, Garsed K, Kelly FM, Zaitoun A, Palva A, Spiller RC, de Vos WM (2014) Faecal microbiota composition and host–microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 63(11):1737–1745

37. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S (2010) Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 22(5):512–519 e114-515

38. Chassard C, Dapoigny M, Scott KP, Crouzet L, Del’homme C, Marquet P, Martin JC, Pickering G, Ardid D, Eschalier A et al (2012) Functional dysbiosis within the gut microbiota of patients with constipated–irritable bowel syndrome. Aliment Pharmacol Ther 35(7):828–838

39. Duboc H, Rainteau D, Rajca S, Humbert L, Farabos D, Maubert M, Grondin V, Jouet P, Bouhassira D, Seksik P et al (2012) Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 24(6):513–520 e246-517

40. Ponnusamy K, Choi JN, Kim J, Lee SY, Lee CH (2011) Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol 60(Pt 6):817–827

41. Rinttila T, Lyra A, Krogius-Kurikka L, Palva A (2011) Real-time PCR analysis of enteric pathogens from fecal samples of irritable bowel syndrome subjects. Gut Pathogens 3(1):6

42. Durban A, Abellan JJ, Jimenez-Hernandez N, Salgado P, Ponce M, Ponce J, Garrigues V, Latorre A, Moya A (2012) Structural alterations of faecal and mucosa-associated bacterial communities in irritable bowel syndrome. Environ Microbiol Rep 4(2):242–247

43. Konig J, Brummer RJ (2014) Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome. Benefic Microbes 5(3):247–261

44. Lagier JC, Khelaifia S, Alou MT et al (2016) Culture of previously uncultured members of the human gut microbiota by culturomics. Nat Microbiol 1:16203

45. Hayashi H, Sakamoto M, Benno Y (2002) Phylogenetic analysis of the human gut microbiota using 16S rDNA clone libraries and strictly anaerobic culture-based methods. Microbiol Immunol 46:535–548

46. De Filippo C, Cavalieri D, Di Paola M et al (2010) Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A 107:14691–14696

47. Shen TD (2017) Diet and gut microbiota in health and disease. Nestle Nutr Inst Workshop Ser 88:117–126

48. Dethlefsen L, Huse S, Sogin ML, Relman DA (2008) The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 6(11):e280

49. Modi SR, Collins JJ, Relman DA (2014) Antibiotics and the gut microbiota. J Clin Invest 124(10):4212–4218

50. Hyland NP, Quigley EM, Brint E (2014) Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain–gut interactions. World J Gastroenterol 20(27):8859–8866

51. Berkes J, Viswanathan VK, Savkovic SD (2003) Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 52:439–451

52. Wirtz S, Neufert C, Weigmann B, Neurath MF (2007) Chemically induced mouse models of intestinal inflammation. Nat Protoc 2(3):541–546

53. Madara JL (1989) Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 83:724–727

54. Smith K, McCoy KD, Macpherson AJ (2007) Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. Semin Immunol 19(2):59–69

55. Abrams GD, Bauer H, Sprinz H (1963) Influence of the normal flora on mucosal morphology and cellular renewal in the ileum. A comparison of germ-free and conventional mice. Lab Invest 12:355–364

56. Swanson PA 2nd, Kumar A, Samarin S, Vijay-Kumar M, Kundu K, Murthy N, Hansen J, Nusrat A, Neish AS (2011) Enteric commensal bacteria potentiate epithelial restitution via reactive oxygen species-mediated inactivation of focal adhesion kinase phosphatases. Proc Natl Acad Sci U S A 108(21):8803–8808

57. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI (2001) Molecular analysis of commensal host–microbial relationships in the intestine. Science 291(5505):881–884

58. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA (2007) Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 9(3):804–816

59. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA (2003) Extracellular MUC3 mucin secretion follows adherence of lactobacillus strains to intestinal epithelial cells in vitro. Gut 52(6):827–833

60. Mattar AF, Teitelbaum DH, Drongowski RA, Yongyi F, Harmon CM, Coran AG (2002) Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr Surg Int 18(7):586–590

61. Ohland CL, Macnaughton WK (2010) Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 298(6):G807–G819

62. Putsep K, Axelsson LG, Boman A, Midtvedt T, Normark S, Boman HG, Andersson M (2000) Germ-free and colonized mice generate the same products from enteric prodefensins. J Biol Chem 275(51):40478–40482

63. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO (2007) Development of the human infant intestinal microbiota. PLoS Biol 5(7):e177

64. Ghosh D, Porter E, Shen B, Lee SK, Wilk D, Drazba J, Yadav SP, Crabb JW, Ganz T, Bevins CL (2002) Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol 3(6):583–590

65. Vivinus-Nebot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, Filippi J, Saint-Paul MC, Tulic MK, Verhasselt V et al (2014) Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 63(5):744–752

66. Diaz Heijtz R, Wang S, Anuar F, Qian Y, Bjorkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S (2011) Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A 108(7):3047–3052

67. Cryan JF, O’Mahony SM (2011) The microbiome–gut–brain axis: from bowel to behavior. Neurogastroenterol Motil: Off J Europ Gastrointestin Motil Soc 23(3):187–192

68. Kennedy PJ, Cryan JF, Dinan TG, Clarke G (2014) Irritable bowel syndrome: a microbiome-gut-brain axis disorder? World J Gastroenterol 20(39):14105–14125

69. O’Malley D, Quigley EM, Dinan TG, Cryan JF (2011) Do interactions between stress and immune responses lead to symptom exacerbations in irritable bowel syndrome? Brain Behav Immun 25(7):1333–1341

70. Santos J, Alonso C, Vicario M, Ramos L, Lobo B, Malagelada JR (2008) Neuropharmacology of stress-induced mucosal inflammation: implications for inflammatory bowel disease and irritable bowel syndrome. Curr Mol Med 8(4):258–273

71. Dinan TG, Quigley EM, Ahmed SM, Scully P, O’Brien S, O’Mahony L, O’Mahony S, Shanahan F, Keeling PW (2006) Hypothalamic–pituitary–gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 130(2):304–311

72. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM (2010) Walkerton health study I: eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 59(5):605–611

73. Dunlop SP, Jenkins D, Neal KR, Spiller RC (2003) Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 125(6):1651–1659

74. Gareau MG, Wine E, Rodrigues DM, Cho JH, Whary MT, Philpott DJ, Macqueen G, Sherman PM (2011) Bacterial infection causes stress-induced memory dysfunction in mice. Gut 60(3):307–317

75. O’Mahony SM, Marchesi JR, Scully P, Codling C, Ceolho AM, Quigley EM, Cryan JF, Dinan TG (2009) Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry 65(3):263–267

76. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF (2011) Ingestion of lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A 108(38):16050–16055

77. Kennedy PJ, Clarke G, Quigley EM, Groeger JA, Dinan TG, Cryan JF (2012) Gut memories: towards a cognitive neurobiology of irritable bowel syndrome. Neurosci Biobehav Rev 36(1):310–340

78. Zomorodi S, Abdi S, Tabatabaee SK (2014) Comparison of long-term effects of cognitive-behavioral therapy versus mindfulness-based therapy on reduction of symptoms among patients suffering from irritable bowel syndrome. Gastroenterol Hepatol Bed Bench 7(2):118–124

79. Li W, Dowd SE, Scurlock B, Acosta-Martinez V, Lyte M (2009) Memory and learning behavior in mice is temporally associated with diet-induced alterations in gut bacteria. Physiol Behav 96(4–5):557–567

80. Ohland CL, Kish L, Bell H, Thiesen A, Hotte N, Pankiv E, Madsen KL (2013) Effects of lactobacillus helveticus on murine behavior are dependent on diet and genotype and correlate with alterations in the gut microbiome. Psychoneuroendocrinology 38(9):1738–1747

81. Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, Guyonnet D, Legrain-Raspaud S, Trotin B, Naliboff B et al (2013) Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 144(7):1394–1401 1401 e1391-1394

82. Mawe GM, Hoffman JM (2013) Serotonin signalling in the gut—functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 10(8):473–486

83. Ruddick JP, Evans AK, Nutt DJ, Lightman SL, Rook GA, Lowry CA (2006) Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med 8(20):1–27

84. Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F, Dinan TG, Cryan JF (2013) The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry 18(6):666–673

85. Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG (2008) The probiotic Bifidobacteria infantis: an assessment of potential antidepressant properties in the rat. J Psychiatr Res 43(2):164–174

86. Holzer P, Reichmann F, Farzi A (2012) Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut–brain axis. Neuropeptides 46(6):261–274

87. Pimentel M, Lin HC, Enayati P, van den Burg B, Lee HR, Chen JH, Park S, Kong Y, Conklin J (2006) Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol 290(6):G1089–G1095

88. Lee HR, Pimentel M (2006) Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth. Curr Gastroenterol Rep 8(4):305–311

89. Kim G, Deepinder F, Morales W, Hwang L, Weitsman S, Chang C, Gunsalus R, Pimentel M (2012) Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. Dig Dis Sci 57(12):3213–3218

90. Fiorucci S, Distrutti E, Cirino G, Wallace JL (2006) The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology 131(1):259–271

91. Carbonero F, Benefiel AC, Gaskins HR (2012) Contributions of the microbial hydrogen economy to colonic homeostasis. Nat Rev Gastroenterol Hepatol 9(9):504–518

92. Teague B, Asiedu S, Moore PK (2002) The smooth muscle relaxant effect of hydrogen sulphide in vitro: evidence for a physiological role to control intestinal contractility. Br J Pharmacol 137(2):139–145

93. Gallego D, Clave P, Donovan J, Rahmati R, Grundy D, Jimenez M, Beyak MJ (2008) The gaseous mediator, hydrogen sulphide, inhibits in vitro motor patterns in the human, rat and mouse colon and jejunum. Neurogastroenterol Motil 20(12):1306–1316

94. Haschke G, Schafer H, Diener M (2002) Effect of butyrate on membrane potential, ionic currents and intracellular Ca2+ concentration in cultured rat myenteric neurones. Neurogastroenterol Motil 14(2):133–142

95. Tazoe H, Otomo Y, Kaji I, Tanaka R, Karaki SI, Kuwahara A (2008) Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J Physiol Pharmacol: Off J Polish Physiol Soc 59(Suppl 2):251–262

96. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A (2011) Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 17(12):1519–1528

97. Treem WR, Ahsan N, Kastoff G, Hyams JS (1996) Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr 23(3):280–286

98. Staudacher HM, Irving PM, Lomer MC, Whelan K (2014) Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol 11(4):256–266

99. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG (2014) A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 146(1):67–75 e65

100. Backhed F, Fraser CM, Ringel Y, Sanders ME, Sartor RB, Sherman PM, Versalovic J, Young V, Finlay BB (2012) Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe 12(5):611–622

101. Arnolds KL, Lozupone CA (2016) Striking a balance with help from our little friends - how the gut microbiota contributes to immune homeostasis. Yale J Biol Med 89(3):389–395

102. Compare D, Nardone G (2013) The role of gut microbiota in the pathogenesis and management of allergic diseases. Europ Rev Med Pharmacologic Sci 17(Suppl 2):11–17

103. Manichanh C, Borruel N, Casellas F, Guarner F (2012) The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 9(10):599–608

104. Kamdar K, Nguyen V, DePaolo RW (2013) Toll-like receptor signaling and regulation of intestinal immunity. Virulence 4(3):207–212

105. Neish AS, Gewirtz AT, Zeng H, Young AN, Hobert ME, Karmali V, Rao AS, Madara JL (2000) Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 289(5484):1560–1563

106. Abreu MT (2010) Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 10(2):131–144

107. Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM (2011) Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 106(2):329–336

108. Belmonte L, Beutheu Youmba S, Bertiaux-Vandaele N, Antonietti M, Lecleire S, Zalar A, Gourcerol G, Leroi AM, Dechelotte P, Coeffier M et al (2012) Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One 7(8):e42777

109. Tattoli I, Petitta C, Scirocco A, Ammoscato F, Cicenia A, Severi C (2012) Microbiota, innate immune system, and gastrointestinal muscle: ongoing studies. J Clin Gastroenterol 46(Suppl):S6–11

110. Wang Y, Devkota S, Musch MW, Jabri B, Nagler C, Antonopoulos DA, Chervonsky A, Chang EB (2010) Regional mucosa associated microbiota determine physiological expression of TLR2 and TLR4 in murine colon. PLoS One 5:e13607

111. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M et al (2007) Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 13(1):35–37

112. Al-Khatib K, Lin HC (2009) Immune activation and gut microbes in irritable bowel syndrome. Gut Liver 3(1):14–19

113. McKendrick MW, Read NW (1994) Irritable bowel syndrome–post salmonella infection. J Infect 29(1):1–3

114. Neal KR, Hebden J, Spiller R (1997) Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 314(7083):779–782

115. Schmulson M, Bielsa MV, Carmona-Sanchez R, Hernandez A, Lopez-Colombo A, Lopez Vidal Y, Pelaez-Luna M, Remes-Troche JM, Tamayo JL, Valdovinos MA (2014) Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: an evidence-based review. Revista de Gastroenterologia de Mexico 79(2):96–134

116. Zoetendal EG, de Vos WM (2014) Effect of diet on the intestinal microbiota and its activity. Curr Opin Gastroenterol 30(2):189–195

117. de Vos WM, Nieuwdorp M (2013) Genomics: a gut prediction. Nature 498(7452):48–49

118. Sundin J, Rangel I, Kumawat AK, Hultgren-Hornquist E, Brummer RJ (2014) Aberrant mucosal lymphocyte number and subsets in the colon of post-infectious irritable bowel syndrome patients. Scand J Gastroenterol 49(9):1068–1075

119. Yang B, Zhou X, Lan C (2015) Changes of cytokine levels in a mouse model of post-infectious irritable bowel syndrome. BMC Gastroenterol 15:43

120. Sundin J, Rangel I, Repsilber D, Brummer RJ (2015) Cytokine response after stimulation with key Commensal bacteria differ in post-infectious irritable bowel syndrome (PI-IBS) patients compared to healthy controls. PLoS One 10(9):e0134836

121. Falk PG, Hooper LV, Midtvedt T, Gordon JI (1998) Creating and maintaining the gastrointestinal ecosystem: what we know and need to know from gnotobiology. Microbiol Mol Biol Rev 62(4):1157–1170

122. O’Mahony C, Scully P, O’Mahony D, Murphy S, O’Brien F, Lyons A, Sherlock G, MacSharry J, Kiely B, Shanahan F et al (2008) Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog 4(8):e1000112

123. O’Hara AM, Shanahan F (2007) Gut microbiota: mining for therapeutic potential. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterologic Assoc 5(3):274–284

124. Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C (1999) Saccharomyces boulardii protease inhibits the effects of Clostridium Difficile toxins a and B in human colonic mucosa. Infect Immun 67(1):302–307

125. Lyra A, Krogius-Kurikka L, Nikkila J, Malinen E, Kajander K, Kurikka K, Korpela R, Palva A (2010) Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. BMC Gastroenterol 10:110

126. Goossens D, Jonkers D, Russel M, Stobberingh E, Van Den Bogaard A, StockbrUgger R (2003) The effect of lactobacillus plantarum 299v on the bacterial composition and metabolic activity in faeces of healthy volunteers: a placebo-controlled study on the onset and duration of effects. Aliment Pharmacol Ther 18(5):495–505

127. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, von Wright A (1999) Persistence of colonization of human colonic mucosa by a probiotic strain, lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol 65(1):351–354

128. Spiller R (2008) Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 28(4):385–396

129. Siitonen S, Vapaatalo H, Salminen S, Gordin A, Saxelin M, Wikberg R, Kirkkola AL (1990) Effect of lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea. Ann Med 22(1):57–59

130. McFarland LV (2006) Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium Difficile disease. Am J Gastroenterol 101(4):812–822

131. McFarland LV (2007) Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis 5(2):97–105

132. Niedzielin K, Kordecki H (2001) A controlled, double-blind, randomized study on the efficacy of lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 13:1143–1147

133. Enck P, Zimmermann K, Menke G, Muller-Lissner S, Martens U, Klosterhalfen S (2008) A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome—a randomized controlled trial with primary care physicians. Neurogastroenterol Motil: Off J Europ Gastrointestin Motil Soc 20(10):1103–1109

134. Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R (2005) A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 22(5):387–394

135. Kajander K, Myllyluoma E, Rajilic-Stojanovic M, Kyronpalo S, Rasmussen M, Jarvenpaa S, Zoetendal EG, de Vos WM, Vapaatalo H, Korpela R (2008) Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 27(1):48–57

136. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101(7):1581–1590

137. O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F et al (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128(3):541–551

138. Ligaarden SC, Axelsson L, Naterstad K, Lydersen S, Farup PG (2010) A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterol 10:16

139. Kruis W, Chrubasik S, Boehm S, Stange C, Schulze J (2012) A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Color Dis 27(4):467–474

140. Roberts LM, McCahon D, Holder R et al (2013) A randomised controlled trial of a probiotic ‘functional food’ in the management of irritable bowel syndrome. BMC Gastroenterol 13:45

141. Choi CH, Jo SY, Park HJ et al (2011) A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 45:679–683

142. Williams EA, Stimpson J, Wang D, Plummer S, Garaiova I, Barker ME, Corfe BM (2009) Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 29(1):97–103

143. Ducrotte P, Sawant P, Jayanthi V (2012) Clinical trial: lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 18(30):4012–4018

144. Agrawal A, Houghton LA, Morris J, Reilly B, Guyonnet D, Goupil Feuillerat N, Schlumberger A, Jakob S, Whorwell PJ (2009) Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 29(1):104–114

145. Hong KS, Kang HW, Im JP, Ji GE, Kim SG, Jung HC, Song IS, Kim JS (2009) Effect of probiotics on symptoms in korean adults with irritable bowel syndrome. Gut Liver 3(2):101–107

146. Sondergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, Ekesbo R (2011) Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. Scand J Gastroenterol 46(6):663–672

147. Dapoigny M, Piche T, Ducrotte P, Lunaud B, Cardot JM, Bernalier-Donadille A (2012) Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study. World J Gastroenterol 18(17):2067–2075

148. Cui S (2012) Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Int J Clin Exp Med 5:238–244

149. Ringel-Kulka T, Palsson OS, Maier D, Carroll I, Galanko JA, Leyer G, Ringel Y (2011) Probiotic bacteria lactobacillus acidophilus NCFM and Bifidobacterium lactis bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol 45(6):518–525

150. Farup PG, Jacobsen M, Ligaarden SC, Rudi K (2012) Probiotics, symptoms, and gut microbiota: what are the relations? A randomized controlled trial in subjects with irritable bowel syndrome. Gastroenterol Res Pract 2012:214102

151. Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS et al (2012) The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 46(3):220–227

152. Niv E, Naftali T, Hallak R, Vaisman N (2005) The efficacy of lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome—a double blind, placebo-controlled, randomized study. Clin Nutr 24(6):925–931

153. O’Sullivan MA, O’Morain CA (2000) Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 32(4):294–301

154. Seifert S, Watzl B (2007) Inulin and oligofructose: review of experimental data on immune modulation. J Nutr 137(11 Suppl):2563S–2567S

155. Vos AP, M’Rabet L, Stahl B, Boehm G, Garssen J (2007) Immune-modulatory effects and potential working mechanisms of orally applied nondigestible carbohydrates. Crit Rev Immunol 27(2):97–140

156. Drakoularakou A, Tzortzis G, Rastall RA, Gibson GR (2010) A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto–oligosaccharide mixture in reducing travellers’ diarrhoea. Eur J Clin Nutr 64(2):146–152

157. Lewis S, Burmeister S, Brazier J (2005) Effect of the prebiotic oligofructose on relapse of Clostridium Difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterologic Assoc 3(5):442–448

158. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR (2009) Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 29(5):508–518

159. Hunter JO, Tuffnell Q, Lee AJ (1999) Controlled trial of oligofructose in the management of irritable bowel syndrome. J Nutr 129(7 Suppl):1451S–1453S

160. Nelis GF, Vermeeren MA, Jansen W (1990) Role of fructose–sorbitol malabsorption in the irritable bowel syndrome. Gastroenterology 99(4):1016–1020

161. Symons P, Jones MP, Kellow JE (1992) Symptom provocation in irritable bowel syndrome. Effects of differing doses of fructose–sorbitol. Scand J Gastroenterol 27(11):940–944

162. Halmos EP, Christophersen CT, Bird AR et al (2015) Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 64:93–100

163. Staudacher HM, Lomer MCE, Farquharson FM, et al. (2017) Diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and probiotic restores Bifidobacterium species: a randomized controlled trial. Gastroenterology [Epub ahead of print]

164. Gibson PR (2017) The evidence base for efficacy of the low FODMAP diet in irritable bowel syndrome: is it ready for prime time as a first-line therapy? J Gastroenterol Hepatol 32(Suppl 1):32–35

165. Pimentel M, Chow EJ, Lin HC (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98(2):412–419

166. Yang J, Lee HR, Low K, Chatterjee S, Pimentel M (2008) Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 53(1):169–174

167. Sachdev AH, Pimentel M (2012) Antibiotics for irritable bowel syndrome: rationale and current evidence. Curr Gastroenterol Rep 14(5):439–445

168. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP et al (2011) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364(1):22–32

169. Menees SB, Maneerattannaporn M, Kim HM (2012) The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 107:28–35